Elamipretide

Investigated uses

• Barth syndrome and multiple mitochondrial/cardiometabolic conditions in clinical development.

Mechanism and hypotheses

• Elamipretide is a mitochondria-targeting aromatic-cationic tetrapeptide; the approved product is intended to affect mitochondrial structure/function, but the precise mechanism of clinical benefit remains incompletely established.
• Hypothesized: Mitochondrial, exercise or anti-aging effects outside the approved Barth-syndrome context remain investigational.

Human evidence

• The randomized 12-week portion of the Barth-syndrome program did not show a significant difference on the key endpoint; longer open-label data contributed to accelerated approval. Limitations: Small rare-disease program; confirmatory evidence remains important.

Safety highlights

• Safety findings are product- and trial-specific; the FDA snapshot should be used for Forzinity rather than extrapolating from gray SS-31.
• Accelerated approval reflects residual uncertainty about clinical benefit and long-term safety.

Regulatory context

Forzinity received accelerated FDA approval for Barth syndrome; gray SS-31/elamipretide vials are not established as the approved product.